The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by Celgene Corporation
Information provided by (Responsible Party):
Celgene Corporation Identifier:
First received: March 27, 2012
Last updated: November 7, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2020
  Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)